Genentech, Inc.
About Genentech, Inc.
1691 articles about Genentech, Inc.
-
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
11/3/2022
Genentech, a member of the Roche Group, announced that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022.
-
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
10/27/2022
Genentech, a member of the Roche Group, announced positive topline results from two global Phase III studies, BALATON and COMINO, evaluating the first and only bispecific antibody for the eye, Vabysmo®, in macular edema due to branch and central retinal vein occlusion.
-
Two Phase III trials of Genentech (Roche)'s Vabysmo hit the primary endpoint in macular edema caused by branch and central retinal vein occlusion, showing non-inferiority to Regeneron's Eylea.
-
Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile
10/26/2022
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new Ocrevus® (ocrelizumab) data on disease progression and healthcare costs in patients with early-stage relapsing-remitting multiple sclerosis (RRMS) and long-term safety from all clinical trials in patients with relapsing MS (RMS) and primary progressive MS (PPMS).
-
Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022
10/19/2022
Genentech, a member of the Roche Group, announced that new Ocrevus® data and continued research into neuromyelitis optica spectrum disorder will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis from October 26-28, 2022.
-
World Muscle Society Congress 2022: Genentech, Fulcrum and Sarepta Present Latest Findings
10/12/2022
The World Muscle Society 2022 Congress is ongoing in Halifax, Canada, with numerous companies presenting cutting-edge research in neuromuscular diseases. Here’s a look. -
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
10/12/2022
Genentech, a member of the Roche Group, announced new two-year data from the JEWELFISH study evaluating Evrysdi® in people with Type 1, 2 or 3 SMA aged 6 months to 60 years at time of enrollment.
-
Genentech and privately-held Arsenal Biosciences forged a multi-year collaboration to identify critical success circuits in T cell-based therapies for solid tumors.
-
Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology
9/27/2022
Arsenal Biosciences, Inc. today announced a multi-year collaboration with Genentech, a member of the Roche Group.
-
NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC.
-
In the second half of the calendar year, the biopharma industry continues to ascend in mergers and acquisitions, new drug approvals and big investments, indicate market confidence and growth.
-
Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
8/18/2022
Jemincare, a leading pharmaceutical company from China, announced that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche and Genentech, a member of the Roche Group, for the development and commercialization of its androgen receptor degrader, JMKX002992.
-
Genentech has partnered with Jemincare to develop and commercialize an asset that may provide new treatment options for people with advanced-stage prostate cancer.
-
Roche Wins Approval for Flu Drug in Young Children, Pfizer Touts Positive Results for Infant Vaccine
8/12/2022
Roche and Pfizer shared positive news from their respective forays into a new pneumococcal vaccine for infants and a treatment for influenza in small children. -
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
8/11/2022
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for Xofluza® for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours.
-
Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine
8/8/2022
Foundation Medicine, Inc., Flatiron Health, and Genentech, members of the Roche Group, in partnership with a network of community oncology practices, today announced new research in the Journal of Thoracic Oncology Clinical and Research Reports.
-
Gravity Branding names Novartis’ Vijoice® (alpelisib)Expert naming process valued in fast-tracked approval as drug clears FDA regulatory hurdles
8/8/2022
Gravity Branding, the agency behind naming blockbuster drugs including Novartis’ Kisqali® (ribociclib), Genentech’s Herceptin® (trastuzumab) and Janssen’s Concerta® (methylphenidate HCl), recently announced its success naming Vijoice® (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).
-
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer's disease.
-
Roche signed a big $6 billion-plus collaboration deal with Poseida on blood cancers while its partner, AC Immune, parsed failed data on an Alzheimer’s drug to suggest a positive spin.
-
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
8/3/2022
Kiniksa Pharmaceuticals, Ltd. today announced a global license agreement with Roche and Genentech, a member of the Roche Group (Genentech), for the rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRβ).